Atara Biotherapeutics, Inc.
ATRA
$7.32
-$0.28-3.68%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 69.07% | 54.12% | 40.55% | -8.44% | -20.95% |
| Total Depreciation and Amortization | 4.60% | 5.68% | 1.91% | -5.12% | -14.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.37% | -19.59% | -13.57% | 334.08% | 360.14% |
| Change in Net Operating Assets | -301.81% | -163.96% | -186.94% | 43.93% | 124.96% |
| Cash from Operations | 64.39% | 52.54% | 33.38% | 17.91% | 28.64% |
| Capital Expenditure | 79.89% | 83.55% | 54.92% | 52.14% | 70.83% |
| Sale of Property, Plant, and Equipment | -- | -100.00% | -- | -99.97% | -99.97% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -92.91% | -90.75% | -33.90% | 231.05% | 11.28% |
| Cash from Investing | -93.04% | -90.80% | -33.74% | 5.75% | -38.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 5.81% | -2.11% | -3.64% | -12.53% | -82.82% |
| Issuance of Common Stock | 1,867.36% | 1,849.29% | 246.78% | 209.09% | -87.13% |
| Repurchase of Common Stock | -5.32% | 93.62% | 93.88% | 93.00% | 84.91% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 46.15% | 86.00% | 14,769.31% | 17,130.68% | 93.23% |
| Cash from Financing | 2,849.35% | 86.42% | -23.37% | -22.56% | -96.21% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 98.79% | -1,104.07% | 43.89% | 74.77% | -366.30% |